Methods Of Treating Multiple Sclerosis

A method of reducing the number of combined unique active lesions (CUALs) in a patient suffering from early-stage multiple sclerosis (ESMS), comprising administering ponesimod to the patient using a regimen that is effective to reduce the number of CUALs by, for example, at least 50%, relative to a patient population at substantially the same level of disease progression receiving a standard of care treatment that does not comprise ponesimod, wherein the patient has a baseline expanded disability status scale (EDSS) score of ≤3.0.

A method of reducing annualized relapse rate (ARR) in a patient suffering from early-stage multiple sclerosis (ESMS), comprising administering ponesimod to the patient using a regimen that is effective to reduce the ARR by, for example, at least 25%, relative to a patient population at substantially the same level of disease progression receiving a standard of care treatment that does not comprise ponesimod, wherein the patient has a baseline expanded disability status scale (EDSS) score of ≤3.0.

A method of reducing MS-fatigue mean difference in a patient suffering from early-stage multiple sclerosis (ESMS) and fatigue, comprising administering ponesimod to the patient using a regimen that is effective to reduce MS-fatigue mean difference, for example, to about −4%, relative to a patient population at substantially the same level of disease progression receiving a standard of care treatment that does not comprise ponesimod, wherein the patient has a baseline expanded disability status scale (EDSS) score of ≤3.0.

A pharmaceutical product comprising ponesimod, wherein the pharmaceutical product is packaged and the package includes instructions for administering ponesimod to a patient having early-stage multiple sclerosis (ESMS) in a regimen that is effective to treat the ESMS, wherein the patient has a baseline expanded disability status scale (EDSS) score of ≤3.0.